@article{97623bf9dab9464fbed96719a841fab0,
title = "The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response",
abstract = "Neurexin-1 (NRXN1) modulates recruitment of NMDA receptors. Furthermore, clozapine reduces hyperactivity of NMDA receptors. Thus, regulation of the NRXN1 gene may mediate the efficacy of clozapine at reducing cortical hyperactivity. We examined the putative functional SNP, rs1045881, for association with schizophrenia, and the potential role of this SNP in clozapine response. The rs1045881 variant was not significantly associated with schizophrenia (N = 302 case-control pairs), but with clozapine response (N = 163; p = 0.030). Baseline and BPRS scores after six months revealed a trend for rs1045881 genotype by treatment interaction (p = 0.079). In the post hoc analysis, a significant association between BPRS negative symptoms score and genotype was observed (p = 0.033). These results suggest that the rs1045881 NRXN1 polymorphism may influence clozapine response.",
keywords = "Antipsychotic medication, Antipsychotic response, Brief Psychiatric Rating Scale, Clozapine, Genetics, NXRN1, Neurexin-1 gene, Pharmacogenetics, Prospective treatment, Schizophrenia",
author = "Lett, {Tristram A P} and Tiwari, {Arun K.} and Meltzer, {Herbert Y.} and Lieberman, {Jeffrey A.} and Potkin, {Steven G.} and Voineskos, {Aristotle N.} and Kennedy, {James L.} and M{\"u}ller, {Daniel J.}",
note = "Funding Information: HYM has received grants or is a consultant to Abbott Labs, ACADIA, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Astra Zeneca, Glaxo Smith Kline, Memory, Cephalon, Minster, Aryx and BiolineRx. HYM is a shareholder of ACADIA. JAL reports that he serves on the Advisory Board of Bioline, GlaxoSmithKline, Intracellular Therapies, Eli Lilly, Pierre Fabre, Psychogenics and Wyeth. He does not receive financial compensation or salary support for his participation as an advisor. He receives grant support from Allon, Forest Labs, Merck and Pfizer; he holds a patent from Repligen. JKL has one time honorarium from Eli Lilly Corporation, and has been a consultant to GSK, Sanofi-Aventis and Dainippon-Sumitomo. Funding Information: CIHR operating grant to DJM (Genetics of antipsychotics induced metabolic syndrome, MOP 89853); NARSAD Young Investigator Award to DJM, CIHR Michael Smith New Investigator Salary Prize for Research in Schizophrenia to DJM, OMHF New Investigator Fellowship to DJM.; the funding sources have no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. ",
year = "2011",
month = nov,
doi = "10.1016/j.schres.2011.08.007",
language = "English (US)",
volume = "132",
pages = "121--124",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",
}
